Page 1

Durability of CRISPR - Cas9 Gene Editing Targeting ANGPTL3 with CTX310 Luke J. Laffin MD Cleveland Clinic C5 Research ESC Congress 2026 Late - Breaking Clinical Trials : Rewriting Cardiovascular Disease on Gene and Molecular Therapies August 28 , 2026 C5Research Cleveland Clinic Coordinating Center for Clinical Research CRISPR THERAPEUTICS Disclosures : Dr. Laffin serves / served as a consultant or on steering committees for Arrowhead , AstraZeneca , Crispr Therapeutics , Diamedica , Eli Lilly , Kardigan , Madrigal , Medtronic , Mineralys , Novo Nordisk , Novartis , Recor , Retension , Ripple , Viking . He receives royalties from Belvoir Media Group , Elsevier , and Springer Nature . NCT07491172